工程FcRn结合动力学大大延长了抗体血清半衰期,并提高了治疗潜力
Sanghwan Ko1, Migyeong Jo2,3, Munsu Kyung1,4
1Department of Biomedical Sciences, Graduate School, Korea University, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Journal of biological engineering
|April 18, 2025
概括
设计了一种Fc变体 (YML) 来优化新生儿Fc受体 (FcRn) 的结合,通过超越内源IgG来显著延长抗体半衰期. 这一突破提高了治疗抗体的持续性和有效性.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 蛋白质工程是指蛋白质工程.
背景情况:
- 在IgG Fc域中优化新生儿Fc受体 (FcRn) 结合是抗体药理动学的关键.
- 治疗性抗体血清持久性依赖于pH依赖的FcRn相互作用,但内源性IgG竞争阻碍了这一点.
- 开发了一种新的Fc变种,以克服竞争并增强FcRn介导的运输.
研究的目的:
- 设计一种具有精确调节的FcRn结合动力学的Fc变体.
- 为了增强FcRn驱动的细胞内传输,并超越内源性IgG.
- 为了实现治疗性抗体血清半衰期的显著改善.
主要方法:
- 综合性定位和突变发生和Fc变异的功能查.
- 鉴定和表征Fc变异YML和EML具有不同的FcRn结合动力学的Fc变异.
- 使用人类FcRn转基因小鼠进行体内验证,以评估血清半衰期延长.
主要成果:
- 这种YML Fc变体在酸性pH下表现出优异的FcRn关联,在中性pH下表现出快速解离.
- 在人类FcRn转基因小鼠中,YML将trastuzumab的血清半衰期延长了6.1倍.
- 在延长血清持久性和保持强大的效应器功能方面,YML在之前报告的Fc工程变异中表现优于之前报告的Fc工程变异.
结论:
- 建立了一个合理的Fc工程框架,以优化FcRn结合动力学,解决内源性IgG竞争.
- 精确控制pH依赖的FcRn结合率和解离率对于Fc工程至关重要.
- YML Fc变种代表了下一代开发具有卓越药理动力学和治疗功效的生物药物的平台.
相关概念视频
Drug Distribution: Plasma Protein Binding
4.4K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.4K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
88
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
88
Drug Distribution: Tissue Binding
2.4K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.4K
Renal Failure: Dose Adjustments
35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
77
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
77
Protein-Drug Binding: Mechanism and Kinetics
144
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
144


